Spots Global Cancer Trial Database for Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans
Official Title: Study of a Short Course of Neoadjuvant Gleevec (Imatinib Mesylate) in Dermatofibrosarcoma Protuberans
Study ID: NCT00243191
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to examine the effect of imatinib on dermatofibrosarcoma protuberan tumors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Pennsylvania Onc/Hem Assoc., Philadelphia, Pennsylvania, United States
MD Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Scott Schuetze, MD, PhD
Affiliation: University of Michigan
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
